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Abstract
Background: Fine needle aspiration (FNA) is widely utilized for evaluation of patients with thyroid
nodules. However, approximately 30% are indeterminate for malignancy. Recently, a mutation in
the BRAF gene has been reported to be the most common genetic event in papillary thyroid
carcinoma (PTC). In this retrospective study, we assessed the utility of BRAF V600E mutation
detection for refining indeterminate preoperative cytologic diagnoses in patients with PTC.
Methods:  Archival indeterminate thyroid FNAs and corresponding formalin-fixed, paraffin-
embedded (FFPE) surgical samples with PTC were identified in our patient files. DNA extracted
from slide scape lysates and 5 µm FFPE sections were evaluated for the BRAF V600E mutation using
LightCycler PCR and fluorescent melting curve analysis (LCPCR). Amplification products that
showed deviation from the wild-type genomic DNA melting peak, discordant FNA and FFPE
matched pairs, and all benign control samples, underwent direct DNA sequencing.
Results: A total of 19 indeterminate thyroid FNAs demonstrating PTC on FFPE surgical samples
were included in the study. Using BRAF mutation analysis, the preoperative diagnosis of PTC was
confirmed in 3/19 (15.8%) FNA samples that could not be conclusively diagnosed on cytology alone.
However, 9/19 (47.4%) FFPE tissue samples were positive for the V600E mutation. Of the
discordant pairs, 5/6 FNAs contained less than 50% tumor cells.
Conclusion: When used with indeterminate FNA samples, BRAF mutation analysis may be a useful
adjunct technique for confirming the diagnosis of malignancy in an otherwise equivocal case.
However, overall tumor cell content of some archival FNA smear slides is a limiting factor for
mutation detection.
Background
While the frequency of thyroid cancer in the general pop-
ulation is relatively low, thyroid nodules are a very com-
mon clinical problem, and palpable thyroid nodules can
be identified in 4–7% of all adults in the United States [1].
The prevalence of malignancy, however, in a solitary thy-
roid nodule is only approximately 5% in normal adults
[2-4]. Consequently, the primary clinical challenge is to
sort out the vast majority of nodules that are benign,
which can generally be followed with surveillance, from
those requiring surgical intervention.
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In 2003, approximately 75–80% of all thyroid cancers
were papillary thyroid carcinoma (PTC) [5]. Among the
most curable of cancers, PTC tends to remain localized in
the thyroid gland, but in time it may metastasize to
regional lymph nodes and, less commonly, to the lungs.
At the time of initial assessment, most patients with PTC
present with a painless, palpable, solitary thyroid nodule.
As early as the1930's, studies reported on the use of fine
needle aspiration (FNA) cytology for the diagnosis of thy-
roid carcinoma [6,7]. However, as often as 30% of the
time, FNA-based evaluation of solitary thyroid nodules
displays limited ability to discriminate between benign
and malignant lesions and an indeterminate cytologic
diagnosis is rendered [8]. Although surgical intervention
is generally recommended following an indeterminate
finding on FNA cytology, malignancy within indetermi-
nate thyroid nodules varies between 3–52% [9-16]. Con-
sequently, planning optimal surgical management in
patients with an uncertain preoperative diagnosis is chal-
lenging.
In view of the increasing number of thyroid nodules that
require FNA evaluation, there is a clear need for the devel-
opment of adjunctive diagnostic assays that would help
refine indeterminate diagnoses on thyroid cytology.
Recently, a single hotspot mutation at nucleotide 1799 of
the BRAF gene has been identified as the most common
genetic event in 29–83% of all cases of PTC [17-27]. This
thymine (T) to adenine (A) transversion mutation results
in the substitution of valine with glutamate (V600E) and
converts BRAF into a dominant transforming protein that
causes constitutive activation of the MAPK pathway, inde-
pendent of RAS activation [28]. Additionally, this muta-
tion appears to be fairly specific for PTC.
In early polymerase chain reaction (PCR) testing plat-
forms, sample DNA or RNA was amplified first and then
detected in a separate step, using a technique such as gel
electrophoresis to assess the size and purity of the prod-
ucts. Recently developed instrumentation combines PCR
amplification and target nucleic acid characterization in
the same closed reaction vessel [29]. Using LightCycler
PCR with fluorescent melting curve analysis (LCPCR), the
difference in melting profiles between mismatched probe/
target and perfectly matched probe/target can be used to
characterize amplification products and indicate the pres-
ence of a mutation [30].
The primary objective of this study was to identify the
BRAF  V600E mutation in thyroid FNA samples using
LCPCR for the purpose of refining indeterminate preoper-
ative cytologic diagnoses in patients with PTC.
Materials and methods
Case and sample selection
This retrospective study was approved by the University of
Utah Institutional Review Board (#13005). Study samples
were identified from a database established by the Univer-
sity of Utah Department of Surgery (University of Utah
Institutional Review Board #11565) of all patients having
undergone treatment for cancer of the thyroid gland at the
University of Utah Hospitals and Clinics from 1994–
2004. This dataset of patients was reviewed to identify
only individuals with both an archival, preoperative FNA
demonstrating cytologic findings indeterminate for
malignancy and follow-up archival surgical pathology for-
malin-fixed, paraffin-embedded (FFPE) tissue demon-
strating PTC. The "indeterminate" cytologic category
encompassed those samples demonstrating hypercellular-
ity suggestive of a follicular or papillary neoplasm and/or
atypical cytomorphologic features suggestive of, but not
diagnostic for, malignancy (Figure 1). The diagnostic cor-
relation was restricted to cases in which the cytology was
reported as indeterminate within a 6-month period pre-
ceding the histology report.
The archival cytologic slides were retrieved from the
cytopathology laboratory slide archives. Only previously-
coverslipped and Diff-Quik stained direct smear slides
were pulled for DNA extraction and mutation analysis. A
case was selected for study inclusion if: age greater than
18; indeterminate cytology report; cytology slide
appeared to contain more than 15% cellularity; follow-up
surgical pathology tissue block was available; and the use
of a single archival cytology slide did not compromise the
patient's permanent slide record. Once identified as avail-
able for mutation analysis, the patient's cytopathology
report was reviewed in order to establish the final cyto-
logic diagnosis and document the area of the thyroid hav-
ing undergone FNA.
The surgical pathology tissue blocks were retrieved from
the surgical pathology laboratory tissue block archives. A
cytopathologist (JSB) reviewed the patient histopathology
reports in order to select only the tissue block that corre-
sponded to the nodule that underwent FNA. If the cytopa-
thology report identified the FNA site as "thyroid-not
otherwise specified, " the tissue block for analysis were
selected from nodules demonstrating PTC.
Finally, we identified matched pairs of preoperative thy-
roid FNA and follow-up FFPE thyroid tissue samples dem-
onstrating benign findings (e.g. nodular goiter,
thyroiditis). This set of samples served as negative controls
for the LCPCR assay.CytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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DNA isolation from FFPE tissue sections
Five 5 µm sections were cut from the FFPE tissues. One tis-
sue section was hematoxylin and eosin (H/E) stained and
coverslipped for review by a cytopathologist (JSB). Using
a pen, the area of the tissue that contained the tumor was
marked. The remaining unstained sections were deparaffi-
nized by immersion in 3 changes of xylene for 5 minutes
each. The tissue sections were then hydrated in a graded
series of ethanol, followed by immersion in dH2O for 1
minute. The slides were allowed to air-dry completely.
The unstained tissue section slide was then inverted over
the H/E-stained slide and the area identified by the
cytopathologist was marked on the underside of the
unstained tissue section slide. Using the circled area of
interest on the unstained tissue section slide as a guide, a
scalpel blade was used to manually scrape the areas of the
tissue containing the tumor cells of interest. Following
manual microdissection, the scalpel blade was inserted
into a clean microcentrifuge tube. A 25.0 µl aliquot of Pro-
teinase K (3 mg/ml) digestion solution (50 mM Tris, 1
mM EDTA, pH8.0, 1% Tween 20) was pipetted onto the
scraped area of the slide to pick up any remaining cells.
The digestion solution was then pipetted from the slide
and used to rinse the scalpel blade that was positioned
inside the labeled microcentrifuge tube.
DNA isolation from FNA samples
A cytopathologist (JSB) assigned each FNA smear slide a
score on based on overall cellularity and atypical cell con-
tent. Overall cellularity scores were as follows:
1+: Unsatisfactory (≤ 1 or 2 clusters of epithelial cells); 2+:
Scant (3–10 clusters of epithelial cells) 3+: Adequate (10–
20 clusters of epithelial cells) 4+: Abundant (> 20 clusters
of epithelial cells with most fields of cells touching). Atyp-
ical cell content scores were as follows: 1+: < 25% atypical
cells; 2+: 25–50% atypical cells; 3+: 50–75% atypical cells;
4+: >75% atypical cells.
Using a pen, the area of the archival FNA slide containing
area of atypical cells of interest was marked. A diamond-
tipped pencil was then used to mark the underside of the
slide indicated by the cytopathologist. Slide coverslips
were detached in xylene, and the slides were hydrated in a
graded series of alcohol, followed by soaking in distilled
water for 2 minutes. The FNA slides were then hydrated in
a graded series of ethanol, followed by immersion in
dH2O for 1 minute. The slides were allowed to air-dry
completely. Using the area of interest indicated by the dia-
mond-tipped pencil marking on the FNA slide as a guide,
slide scrape lysates (SLL) were prepared by using a single-
edged razor blade to scrape the areas of the slide contain-
ing the atypical cells of interest. Following manual micro-
dissection, a 50.0 µl aliquot of Proteinase K (3 mg/ml)
digestion solution (50 mM Tris, 1 mM EDTA, pH 8.0, 1%
Tween 20) was pipetted onto the scraped area of the slide
to pick up any remaining cells. Using the same pipette tip,
the digestion solution was then pipetted from the slide
and used to rinse the scalpel blade that was positioned
inside the labeled microcentrifuge tube.
DNA extraction
The samples were incubated in the digestion solution at
55°C for 12–16 hours. Following centrifugation at 12,000
rpm for 5 minutes, the supernatant was transferred into a
newly labeled microcentrifuge tube. The samples were
then placed into a 95°C heat block for 10 minutes to inac-
tivate the proteinase K. All FFPE tissue sample DNA was
diluted to a working concentration of 50 ng/µl prior to
amplification. A MicroSpin G25 (Amersham Bioscience,
Example of indeterminate thyroid fine needle aspiration  (FNA) Figure 1
Example of indeterminate thyroid fine needle aspiration 
(FNA). Fine needle aspirate sample from 28 year-old female 
with thyroid nodule. Case was interpreted as "fragments of 
atypical epithelial cells in a background of reactive lym-
phocytes. A follicular neoplasm or papillary carcinoma cannot 
be excluded." The thyroidectomy specimen showed a classi-
cal papillary thyroid carcinoma in the corresponding lobe of 
the thyroid.CytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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Sweden) sephadex column was routinely used for all FNA
samples following DNA extraction. Fine needle aspiration
sample DNA then underwent PCR without additional
dilution. Following DNA extraction, all samples were
stored at -20°C prior to analysis.
Characterization of control material
To assess the sensitivity and specificity of the LCPCR
method for detection of the BRAF V600E mutation, three
cell lines were analyzed. A human PTC-derived cell line
(NPA) was characterized for use as a positive control,
while one follicular thyroid carcinoma (ROW-1), and one
colorectal carcinoma (HCT116) cell lines were character-
ized for use as negative controls. All cell lines were grown
to a concentration of 3 × 106 cells per ml, trypsinized, and
transferred to a 1.5 ml microcentrifuge tube. Cell line
DNA was isolated and purified using the QIAamp DNA
Mini Kit (QIAGEN Inc., Valencia, CA). DNA concentra-
tion and purity was determined and all cell lines were
diluted to a working concentration of 50 ng/µl and stored
at 4°C.
Polymerase chain reaction and fluorescent melting curve 
analysis
For this study, a pair of oligonucleotide primers were
designed to amplify a 250 base-pair region of exon 15 in
the BRAF gene:
forward: 5'CTCTTCATAATGCTTGCTCTGATAGG-3 and
reverse: 5'TAGTAACTCAGCAGCATCTCAGG-3' (Inte-
grated DNA Technologies, Inc, Coralville, IA).
Two fluorescent hybridization probes were designed to
detect the BRAF V600E mutation: 23 sensor: 5'-AGCTA-
CAGTGAAATCTCGATGGAG-Fluoroscein-3' and
anchor: 5'-LCRed640-GGTCCCATCAGTTTGAACAGTT-
GTCTGGA-Phosphate-3'
with the sensor probe spanning nucleotide position 1799
(Idaho Technologies, Salt Lake City, UT). Amplification
was performed in glass capillaries using 50 ng of tissue or
FNA (range 12.0 to 110.0 ng) sample DNA in a 10 µl vol-
ume containing 1 ul of 10× LightCycler DNA Master
Hybridization Probes (Roche Molecular Biochemicals,
Mannheim), 0.8 µl of 25 mM MgCl2, 1 µl (5 µM) forward
and reverse primer, and 1 µl (2 µM) anchor and sensor
hybridization probe. The reaction mixture underwent 45
cycles of rapid PCR. Post amplification fluorescent melt-
ing curve analysis was performed by gradual heating of
the samples at a rate of 0.1°C per second from 45°C to
95°C. Fluorescent melting peaks were determined by
plotting of the negative derivative of fluorescence (F) with
respect to temperature (T), or -dF/dT.
Limit of detection experiment
A limit of detection experiment was first conducted to
determine the percent of tumor with normal cell contam-
ination in which abnormal melts were detectable by
LCPCR. The NPA cell line was diluted with human
genomic wild-type (WT) DNA to 99% tumor, 95% tumor,
90% tumor, 75% tumor, 50% tumor, 25% tumor, 10%
tumor, and 5% tumor. In addition, 100% NPA and 100%
WT samples were tested. Each dilution was run in dupli-
cate.
DNA sequencing analysis
All PCR products that showed deviation from the WT
genomic DNA melting peak, as well as any discordant
FNA and FFPE matched pairs, and benign control samples
were confirmed by direct sequencing of exon 15. Ten ul of
amplified sample plus 1.0 ul of Biotracker 6× tracking dye
(Bioventures, San Francisco) was loaded into the sample
wells of a 2% agarose DNA gel and electrophoresed at 70
volts. To isolate the DNA from the agarose gel, the desired
ethidium-stained band was viewed with a UV transillumi-
nator and excised using a razor blade. Sample DNA was
then extracted from the agarose gel using a nebulizer (Mil-
lipore, Bellirica, MA). Bidirectional DNA sequence data
was generated for each sample using fluorescently labeled
terminator sequencing chemistry and sequencing primers
(5' primer and 3' primer). DNA sequencing data files from
the purified sequencing reaction products were generated
using an ABI Prism 3100 Genetic Analyzer (Applied Bio-
systems).
Results
A total of 24 archival FNA (indeterminate n = 19; benign
n = 5) and FFPE matched pair samples were evaluated for
the BRAF V600E point mutation using LCPCR.
Characterization of control material
A homozygous T→A mutation was identified in the BRAF
gene (exon 15) at nucleotide 1799 in the NPA cell line,
which is derived from PTC. The NPA cell line served as a
positive control for BRAF  V600E mutation analysis by
LCPCR. To assess the specificity of the LCPCR method for
detection of the BRAF V600E mutation, cell lines ROW-1
(follicular thyroid carcinoma) and HCT116 (colorectal
carcinoma) underwent mutation analysis. Both ROW-1
and HCT115 cell lines showed a WT BRAF  sequence.
These findings were confirmed by direct DNA sequencing.
LCPCR limit of detection
Results of the limit of detection experiments confirmed
that the 1 base pair change in the BRAF mutation was
detectable down to the level of 25% tumor when a
homozygous mutant cell line was used as a control. Con-
sequently, it was determined that the results of LCPCR for
detection of the heterozygous BRAF V600E mutation inCytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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Table 1: Clinicopathologic features and BRAF V600E mutation analysis results of 19 indeterminate thyroid FNA cases. Median patient 
age = 40 years.
Age Sex Cytologic Interpretation Mutation Status 
FNA
Sequencing 
Result FNA
Surgical 
Pathology
Mutation Status 
Tissue
Sequencing 
Result Tissue
59 M Highly atypical cells suspicious 
for follicular or papillary 
neoplasm
WT WT PTC; FV MUT MUT
34 F Atypical follicular epithelium, 
cannot exclude follicular 
neoplasm
WT WT PTC MUT MUT
32 F Atypical cells present suspicious 
for PTC
MUT MUT PTC MUT MUT
31 F Atypical follicular cells; cellular 
pattern consistent with 
follicular neoplasm
MUT MUT PTC MUT MUT
54 M Hurthle cell neoplasm with 
cystic degeneration
WT WT PTC; FV MUT MUT
13 F Atypical cells suspicious for 
papillary or follicular lesion
WT PTC WT
53 F Atypical follicular cells 
consistent with follicular 
neoplasm
MUT MUT PTC MUT MUT
43 F Suspicious but not diagnostic of 
PTC
WT PTC WT
23 M Highly atypical cells present 
suspicious for PTC
WT PTC; FV WT
26 F Follicular proliferation most 
consistent with a nodular goiter
WT WT PTC MUT MUT
37 M Atypical folllicular epithelim, 
cannot exclude a follicular 
neoplasm
WT PTC WT
26 M Atypical cells suspicious for 
PTC
WT PTC WT
55 M Suspicious for a follicular 
neoplasm
WT PTC WT
29 F Atypical cells present suspicious 
for follicular or papillary 
neoplasm
WT PTC WT
57 F Atypical follicular cells in a 
background of lymphoid cells
WT WT PTC MUT MUT
54 F Follicular neoplasm cannot be 
excluded
WT PTC; FV WT
50 F Follicular neoplasm cannot be 
excluded
WT PTC; FV WT
28 F Fragments of atypical epithelial 
cells; cannot exclude follicular 
neoplasm or PTC
WT WT PTC MUT MUT
64 F Hyperplastic nodule vs. 
follicular neoplasm
WT PTC WT
PTC = papillary thyroid carcinoma; FV = follicular variant; WT = wild-type BRAF V600E genotype; MUT = mutant BRAF V600E genotype (exon 15)CytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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FNA or FFPE samples containing less than 50% tumor
cells may not be accurate.
Prevalence of BRAF V600E mutation in indeterminate 
thyroid fine needle aspirates
Using LCPCR and DNA sequencing, BRAF mutation anal-
ysis confirmed the preoperative diagnosis of PTC in 3/19
(15.8%) of the cases in the indeterminate group. Nine of
19 (47.4%) corresponding FFPE surgical samples col-
lected from the same patients were positive for the BRAF
mutation (Table 1).
There was a 69% rate of concordance for BRAF mutation
status between paired indeterminate FNA and malignant
FFPE tissue specimens. Six FNA samples were negative for
the BRAF V600E mutation, while the corresponding FFPE
tissue samples were positive. Of these, 5/6 FNA samples
contained less than 50% tumor cells. Conversely, an inde-
terminate FNA containing >75% atypical cells failed to
demonstrate the mutation, while the resected tumor was
positive for the mutation. The overall cellularity of this
sample was scored at a 2+.
Melting curve analysis revealed that for the FNA samples,
the WT sequence (GTG) Tm was 65.34°C ± 0.37°C, the
GTG→GAG mutation at nucleotide 1799, resulted in a
shift of Tm to 60.23°C ± 0.53°C (Figure 1). For the FFPE
samples, the WT Tm was 64.92°C ± 0.35°C, while the
mutant Tm was 60.11°C ± 0.46°C (Figure 2).
Bidirectional DNA sequencing revealed that all BRAF
mutations were heterozygous and involved a T→A substi-
tution at nucleotide 1799. The LCPCR assay demonstrated
100% concordance between melting curve and DNA
sequence results. 0/5 benign thyroid FNA and matching
FFPE samples were also found to be negative for the muta-
tion.
Discussion
As often as 30% of the time, FNA cytology displays limited
ability to discriminate between benign and malignant thy-
roid lesions, and an indeterminate diagnosis is rendered
[31]. Some clinicians feel that total thyroidectomy is
appropriate for patients with an indeterminate FNA cytol-
ogy result [9,10,32]. Proponents of this approach argue
that it eliminates the probability of thyroid cancer recur-
rence [33-36]. Alternatively, if the suspect nodule is small,
some clinicians opt to perform a hemi-thyroidectomy
procedure following an indeterminate cytology result
[37]. Considered the minimum extent of surgery for a thy-
roid nodule, this procedure reduces the risk of postopera-
tive complications associated with total thyroidectomy,
such as hypoparathyroidism and laryngeal nerve injury
[38]. However, depending on patient/tumor risk stratifi-
cation, postoperative confirmation of malignancy usually
results in a second-stage completion thyroidectomy,
which is associated with higher morbidity than initial
total thyroidectomy [39]. Regardless of the choice of sur-
gical procedure, the incidence of malignancy in patients
with indeterminate cytology findings varies greatly. Con-
sequently, a large percentage of these patients would ben-
efit from a method that improves the diagnosis of
preoperative thyroid aspirate material.
A number of molecular markers have been evaluated as
possible adjunct tests for refining the diagnosis of PTC on
FNA. However, the predictive value of these markers has
been limited to date due to a lack of specificity or sensitiv-
ity [40]. Expressed by malignant thyrocytes, galectin 3 is a
β-galactoside-binding protein that was initially believed
to be a marker specific for PTC [41]. Further analysis has
revealed, however, that identification of this protein may
be less reliable in conditions involving lymphocytic infil-
tration, such as Hashimoto's thyroiditis [42]. HBME-1 is a
monoclonal antibody that recognizes an epitope
expressed in malignant mesothelioma and other adeno-
carcinomas, as well as PTC and follicular thyroid tumors
[43,44]. Although benign thyroid lesions do not express
immunoreactivity for HBME-1 [44], positive staining has
been found in malignant thyroid tumors besides those of
papillary differentiation [45]. Telomerase is a specialized
reverse transcriptase enzyme that maintains chromosome
ends. Detection of telomerase expression by reverse-tran-
scriptase PCR originally showed promising sensitivity and
specificity for PTC diagnosis [46], but telomerase repeat
amplification (TRAP) has identified high expression of
this molecule in FNA specimens from benign nodules
[47]. Up to 95% of PTC demonstrate strong immunos-
taining with cytokeratin 19 (CK19) [48]. However, CK19
immunoreactivity is not specific for PTC, as positive
immunoreactivity has been identified in benign follicular
adenomas [49]. Aberrant expression of the RET proto-
oncogene results from chromosomal rearrangements in
which the tyrosine kinase domain of RET is fused to the 5'-
terminal region of an unrelated gene, leading to the gen-
eration of fusion proteins known as ret rearrangements in
PTC (RET/PTC). Although RET/PTC rearrangements have
been identified in a large percentage of PTC in individuals
exposed to external radiation [50], a relatively high fre-
quency of RET/PTC rearrangements have also been found
in benign nodular thyroid diseases of patients exposed to
nuclear fallout and in benign conditions such as trabecu-
lar adenomas and Hashimoto's thyroiditis [51].
The mutation at V600E in the BRAF kinase gene appears
to be an attractive molecular marker for thyroid cancer
diagnosis as it has been found to be the most common
genetic event in PTC, while being highly specific for this
tumor (Table 2). The goal of this study was to identify the
BRAF  V600E mutation in thyroid FNA samples in anCytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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attempt to determine if BRAF mutation analysis can serve
as a useful adjunct technique in indeterminate cytologic
diagnoses. The use of LCPCR was chosen for SNP detec-
tion because both gene amplification and allele analysis
could be performed in a homogeneous, closed-tube sys-
tem on the same instrument. Increased specificity for
mutation detection is realized due to the hybridization of
two independent probes and the fact that the probe melt-
ing temperature is sequence specific. Of the cases evalu-
ated in this study, which included 24 matched pairs of
FNA and FFPE surgical tissues, there were no false positive
BRAF  mutation results by LCPCR and LCPCR demon-
strated 100% concordance with DNA sequencing results.
Previous investigators have also reported on use of the
LCPCR method for detecting the V600E activating point
mutation in the BRAF  gene. In contrast to the present
study, which analyzed archival FNA and FFPE surgical
material for mutation detection, these groups utilized pri-
marily cell lines or a combination of cell lines and FFPE
surgical material. Nikiforova et al. evaluated thyroid
tumors and anaplastic carcinoma cell lines to demon-
strate that BRAF mutations, which in thyroid tumors were
originally thought to be restricted to papillary carcinomas,
also occur in poorly differentiated and anaplastic carcino-
mas [23]. Among 259 thyroid tumor samples screened,
this group demonstrated a 100% correlation in BRAF
V600E detection rate between LCPCR and single strand
conformational polymorphism. This finding is in agree-
ment with the results of the present study, in which
LCPCR assay demonstrated 100% concordance between
melting curve and DNA sequencing results. In contrast to
the present study, however, Nikiforova used laser capture
microdissection (LCM) to obtain DNA either from a small
focus of papillary microcarcinoma or to study well-differ-
entiated and poorly differentiated or anaplastic areas
within the same tumor. Ikenoue et al. analyzed 12 colon
and 9 gastric cancer cell lines by LCPCR for presence of the
BRAF V600E mutation [52]. Using a mixture of standard
DNA, Ikenoue determined that as little as 10% V600E
mutant DNA could be identified in a background of WT
DNA. In the present study, results of the limit of detection
experiments confirmed that the 1 base pair change in the
BRAF mutation was detectable down to the level of 25%
tumor when a homozygous mutant cell line was used as a
control. Consequently, it was determined that the results
of LCPCR for detection of the heterozygous BRAF V600E
mutation in FNA or FFPE samples containing less than
50% tumor cells may not be accurate. It is s possible that
the level of sensitivity might be increased through the use
of a technique such as LCM of the archival FNA slide
material. As demonstrated by Nikiforova, et al, using LCM
can significantly enhance the sensitivity for identifying
mutant DNA in the presence of WT DNA, as the captured
sample contains almost exclusively tumor cells.
In the present study, the preoperative diagnosis of PTC
was confirmed in 3/19 (15.8%) indeterminate FNA sam-
ples that could not be conclusively diagnosed by cytology
alone. This finding is consistent with reported mutation
prevalence rates in indeterminate thyroid FNA cases
(Table 3) [27,53,54]. However, 9/19 (47.4%) correspond-
ing FFPE surgical samples collected from the same
patients were positive for the mutation, for a 69% rate of
concordance between the sample types. Of the 6 discord-
ant FNA cases in this study, 5/6 (83%) contained <50%
atypical cells. Because tumor DNA from FNA samples is
invariably contaminated with the WT allele of the gene in
question, the somatically mutated allele can be difficult to
distinguish. This results in reduced sensitivity for identify-
ing mutant DNA in the presence of WT DNA. Results of
the limit of detection experiments confirmed that the one
base pair change in the BRAF mutation was detectable by
LCPCR down to the level of 25% tumor when a
homozygous mutant cell line was used as a control.
Because the BRAF  V600E mutation in PTC is hetero-
zygous, a detection limit of 50% atypical cells was estab-
Melting curve analysis of BRAF mutations in thyroid FNA  samples Figure 2
Melting curve analysis of BRAF mutations in thyroid FNA 
samples. Overlapping fluorescein-labeled oligonucleotide 
probes were used to scan extracted DNA for mutations in 
exon 15 of BRAF. Multiple probes complementary to the 
wild-type (WT) sequences were placed within the same 
reaction, and the different sites were identified by their spe-
cific probe/target duplex melting temperatures. The position 
of each probe/target melting temperature and the relative 
ratio of the melting peak areas determined WT profiles. 
After amplification in a LightCycler, the instrument begins a 
melting program where the reactions are cooled to anneal 
the probes and then slowly heated (0.1°C/s) while fluores-
cence is continuously monitored. Somatic mutations are 
identified by changes from a characteristic WT melting curve 
profile. When melting curves from non-mutated and mutated 
samples are compared, additional melting peaks or changes in 
peak-area ratios indicate a sequence alteration (nucleotide 
mismatch) under the probe. Melting curve analysis revealed 
that for the WT BRAF sequence (GTG) Tm was 65.34°C ± 
0.37°C, the GTG→GAG mutation at nucleotide 1799, 
resulted in a shift to 60.23°C ± 0.53°C.CytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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lished for the LCPCR assay, below which the results of
LCPCR might not be accurate. Because LCPCR and DNA
sequencing results were in 100% agreement for all sam-
ples, it is likely that the percentage of BRAF mutant DNA
in the discordant FNA samples was below the limit of
detection for both methods.
Other investigators have also experienced varying degrees
of concordance for BRAF  mutation status between
matched FNA and FFPE samples. Cohen et al. noted dis-
cordant results in 3/49 matched pair samples for a 94%
rate of concordance between the sample types [53]. Of the
three discordant FNA samples in Cohen's study, the muta-
tion was not detected in 2 FNAs while the resected tumors
harbored the mutation. In these 2 cases, the FNA material
was found to be sparsely cellular. These previous findings,
combined with those of the present study, confirm that
overall tumor cell content of the FNA sample is critical for
mutation detection, whether by LCPCR or another
method.
If the results of the limit of detection experiments in the
present study were used to select samples for mutation
analysis, thereby excluding from analysis any FNA sample
that contained <50% atypical cells, 2/8 indeterminate
FNA samples would have been found to harbor the BRAF
mutation. The resulting BRAF positivity rate in the inde-
terminate FNA samples would, therefore, be 25% rather
than 15.8%. In actual clinical practice, the pathologist
would control pre-analytic probability by carefully select-
ing which indeterminate thyroid FNAs would be referred
for mutation analysis, based upon the cellular composi-
tion of the smears and/or the needle rinse pellet.
It is also possible that the discordant aspirate material in
the present study contained only the BRAF WT genotype,
and that the mutant DNA identified in the resected tumor
samples was the result of an early tumorigenic event.
However, this is an unlikely scenario, as inclusion criteria
allowed cases to be selected for mutation analysis only if
the cytology was reported as abnormal within a six-month
period preceding the histology report. This restriction was
instituted in an attempt to reduce mutation status discord-
Table 3: BRAF V600E mutation prevalence rates in indeterminate thyroid FNA cases
Series Number of indeterminate thyroid FNA's 
evaluated
Number (%) with BRAF V600E mutation
Salvatore, et al. 2004 15 4 (27)
Cohen, et al. 2004 32 5 (16)
Xing, et al. 2004 25 2 (8.3)
Total 72 11 (15.3)
Table 2: BRAF V600E mutation prevalence in various thyroid neoplasms.
Series FA FTC MTC PTC (%)
Cohen et al. J Natl Cancer 
Inst 2003
0/20 0/13 0/3 24/35 (69)
Kimura et al. Cancer Res 
2003
0/14 0/10 28/78 (36)
Fukushima et al. Oncogene 
2003
0/8 0/9 40/76 (53)
Soares et al. Oncogene 
2003
0/51 0/18 23/50 (46)
Namba et al. J Clin 
Endocrinol Metab 2003
0/20 0/11 49/170 (29)
Nikiforova et al. J Clin 
Endocrinol Metab 2003
0/46 0/32 0/13 45/119 (38)
Xu et al. Cancer Res 2003 0/18 21/56 (38)
Kim et al. Yonsei Med J 
2004
58/70 (83)
Trovisco et al. J Pathol 
2004
28/53 (53)
Xing et al. J Clin Endocrinol 
Metab 2004
0/43 0/14 0/14 17/38 (45)
Salvatore, G et al. J Clin 
Endocrinol Metab 2004
0/19 26/69 (38)
Total 0/231 0/106 0/37 359/814
FA = follicular adenoma; FTC = follicular thyroid carcinoma; MTC = medullary thyroid carcinoma; PTC = papillary thyroid carcinomaCytoJournal 2006, 3:10 http://www.cytojournal.com/content/3/1/10
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ance between the sample types. Five of the six discordant
FNA cases were collected within one month prior to the
FFPE surgical tissue.
Because PTC is frequently multifocal, there has been spec-
ulation regarding whether noncontiguous tumor foci arise
from intraglandular metastases from a single primary
tumor or originate as unrelated clones derived from inde-
pendent tumors. A recent study by Shattuck et al. [55]
used PCR to evaluate the patterns of X chromosome inac-
tivation of multiple distinct foci of PTC from 17 women.
Discordant patterns indicative of independent origins
were identified in tumors from 5 patients, leading to the
conclusion that individual tumor foci in patients with
multifocal PTC often arise as independent tumors. This
finding could explain why an indeterminate FNA contain-
ing >75% atypical cells in the present study failed to dem-
onstrate the mutation, while the resected tumor was
positive for the mutation. The possibility exists that the
tumor identified in the resected tissue, and in the nodule
sampled by FNA, did not share the same clonal origin.
While the hotspot mutation at V600E is the most com-
mon genetic event in PTC, recent studies have demon-
strated that up to 9% of follicular variant of PTC (FVPTC)
cases demonstrate a mutation in codon 601 of the BRAF
gene, resulting in the substitution of lysine with glutamate
(K601E) [25,56]. Although five of the indeterminate thy-
roid FNA cases in the present study were classified histo-
logically as FVPTC, none were found to contain the K601E
mutation. However, because the hybridization probes
were designed as a perfect match to the BRAF WT geno-
type, other mutations covered by the probe would likely
lead to a different temperature profile and probable detec-
tion of the K601E mutation.
Because the number of samples analyzed in the present
study was limited, and the tumor cell content of some of
the archival samples was scant, we were unable to deter-
mine the full diagnostic utility of LCPCR detection of the
BRAF activating point mutation on indeterminate thyroid
aspirates. Although molecular techniques such as LCPCR
may be useful for refining a diagnosis of PTC, the absence
of a BRAF mutation does not exclude the possibility of a
malignant condition. In view of the large number of pal-
pable thyroid nodules that require evaluation by FNA, a
search for molecular markers such as BRAF may have clin-
ical utility.
The results suggest that detection of BRAF mutation in
thyroid aspirates may enhance the accuracy of FNA and
refine preoperative diagnosis of PTC.
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